Efficacy of Chinese medicine WW-1 in managing gastric atrophy and intestinal metaplasia in patients with chronic atrophic gastritis: A multicenter, randomized, double-blind, placebo-controlled trial

医学 胃肠病学 内科学 中医药 萎缩性胃炎 肠化生 萎缩 化生 临床试验 病理
作者
Yang Yang,Zongshi Qin,Sijing Du,Shuangshuang Fang,Yanjun Ma,Zhaolan Liu,Weixun Zhou,Xiuli Liu,Chin Yen Tay,Yanping Tang,Chuijie Wang,Juanpin Su,Fengbin Liu,Jin Lian Shu,Xudong Tian,Qian Yang,Huayi Liu,Li Liu,Yu Tao,Zhenhua Li
出处
期刊:Pharmacological Research [Elsevier BV]
卷期号:227: 108176-108176 被引量:8
标识
DOI:10.1016/j.phrs.2026.108176
摘要

Chronic atrophic gastritis (CAG) is a well-recognized precancerous condition for which effective pharmacological interventions remain limited. Qilianxiaopi Decoction (WW-1), a traditional Chinese medicine formula, has been widely used for gastric disorders and has shown potential anti-inflammatory and mucosal-protective effects. In this multicenter, randomized, double-blind, placebo-controlled trial with centralized blinded histological review, 468 patients with CAG were randomly assigned in a 2:1 ratio to receive WW-1 or placebo for 24 weeks, followed by a 24-week observation period. The primary endpoint was the change in histological gastric atrophy scores from baseline to week 48, assessed according to the updated Sydney system. Secondary outcomes included changes in intestinal metaplasia (IM), OLGA and OLGIM staging, serum pepsinogen levels, and markers of gastric mucosal barrier integrity. WW-1 significantly improved corpus GA at the end of treatment (OR=1.74, P = 0.016) and at follow-up (OR=1.75, P = 0.014). Significant improvement in corpus IM was observed at week 24 (OR=1.75, P = 0.013), with delayed benefits in the incisura angularis for both GA (OR=1.56, P = 0.034) and IM (OR=1.58, P = 0.026) at follow-up. WW-1 also improved OLGA staging (OR=1.54, P = 0.034). Adverse events were comparable between groups. The WW-1 group showed consistently higher serum PGI levels both post-treatment (median: 84.81 vs. 73.17 μg/L, P = 0.009) and at follow-up (median: 85.92 vs. 82.76 μg/L, P = 0.031), along with enhanced mucosal expression of E-cadherin, occludin, and ZO-1 (all P < 0.001). Compared with current Western medical strategies, which primarily rely on Helicobacter pylori eradication and surveillance but offer limited efficacy in reversing established atrophy or IM, WW-1 demonstrated a favorable balance of efficacy and safety, with its therapeutic benefits primarily observed in the gastric corpus and incisura angularis. This suggests its potential as a complementary therapeutic option for CAG.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Anonymous完成签到,获得积分0
2秒前
molihuakai的应助被WYL采纳,获得10
2秒前
3秒前
LIUDAN发布了新的文献求助10
3秒前
ertredffg完成签到,获得积分10
3秒前
基金中中中完成签到,获得积分10
4秒前
FXQ完成签到,获得积分10
5秒前
ZHENG发布了新的文献求助10
5秒前
韭菜馅发布了新的文献求助10
5秒前
6秒前
Lsmile完成签到 ,获得积分10
7秒前
论高等数学的无用性完成签到 ,获得积分10
7秒前
Hugo发布了新的文献求助10
7秒前
taoshiren发布了新的文献求助10
7秒前
丰富俊驰完成签到 ,获得积分10
8秒前
didi完成签到 ,获得积分10
8秒前
NexusExplorer的应助被FaFa采纳,获得10
8秒前
li完成签到,获得积分10
8秒前
甜甜薯片完成签到,获得积分10
11秒前
充电宝的应助被ohooo采纳,获得10
11秒前
11秒前
顺利毕业完成签到 ,获得积分10
12秒前
shenkekeshen的应助被春申君采纳,获得10
12秒前
15秒前
外向新梅发布了新的文献求助10
15秒前
15秒前
15秒前
科研通AI2S的应助被难过的煎饼采纳,获得10
16秒前
田様的应助被Karry采纳,获得10
16秒前
思源的应助被嘟嘟大魔王采纳,获得50
16秒前
16秒前
17秒前
17秒前
18秒前
18秒前
ZHENG完成签到,获得积分10
18秒前
18秒前
shenkekeshen的应助被职克琪采纳,获得10
19秒前
YAMABUKI完成签到,获得积分10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189302
求助须知:如何正确求助?哪些是违规求助? 9576666
关于积分的说明 21849295
捐赠科研通 7787245
什么是DOI,文献DOI怎么找? 3435521
关于科研通互助平台的介绍 2559748
邀请新用户注册赠送积分活动 2482509